-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The risk of diabetes (DM) is known to increase in patients with rheumatoid arthritis (RA).
study aims to determine the association between RA disease activity, including the assessment of specific cytokines and cytokines, and DM.
were adult RA patients diagnosed by physicians on the Department of Veterans Affairs rheumatoid arthritis registry.
as part of clinical treatment, the disease activity and clinical evaluation were carried out vertically.
30 cytokines and coercion factors in the serum were measured when they were entered into the group.
DM is defined by algorithms that use diagnostic codes and drugs.
the association between clinical factors and DM incidence using multi-factor Cox proportional risk models.
the association between cytokines/convergence factors and DM was assessed after adjusting for age, gender, race, smoking, body mass index (BMI) and medication.
results were as follows: of the 1866 RA patients who did not have DM at the time of joining the group, 9223 patients were followed - after 130 cases had DM.
disease activity score (DAS28)-C reactive protein (CRP), obesity, age and men are associated with an increased risk of DM, while current smoking and methotrexate use have protective effects.
who use methotrexate have a lower risk of DM.
several cytokines/convergence factors were independently associated with DM morbidity, including interletin (IL)-1, IL-6, and macrophage-derived cytokines/convergence factors (HR range 1.11-1.26).
these associations are not related to DAS28-CRP.
, it can be seen that in RA patients, high disease activity and increased cytokine/cytokine levels are associated with an increased risk of DM.
the future, it is possible to study whether targeted treatment of high-risk populations can prevent the occurrence of DM.